company background image
MRC

Mercator Medical WSE:MRC Stock Report

Last Price

zł48.50

Market Cap

zł516.4m

7D

5.7%

1Y

-67.9%

Updated

24 Sep, 2022

Data

Company Financials +
MRC fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

MRC Stock Overview

Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally.

Mercator Medical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mercator Medical
Historical stock prices
Current Share Pricezł48.50
52 Week Highzł168.35
52 Week Lowzł45.10
Beta3.55
1 Month Change-15.45%
3 Month Change-7.20%
1 Year Change-67.88%
3 Year Change789.91%
5 Year Change201.24%
Change since IPO231.06%

Recent News & Updates

Sep 23
Returns At Mercator Medical (WSE:MRC) Are On The Way Up

Returns At Mercator Medical (WSE:MRC) Are On The Way Up

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

Shareholder Returns

MRCPL Medical EquipmentPL Market
7D5.7%-0.6%-2.4%
1Y-67.9%-45.8%-32.1%

Return vs Industry: MRC underperformed the Polish Medical Equipment industry which returned -45.8% over the past year.

Return vs Market: MRC underperformed the Polish Market which returned -32.1% over the past year.

Price Volatility

Is MRC's price volatile compared to industry and market?
MRC volatility
MRC Average Weekly Movement10.7%
Medical Equipment Industry Average Movement10.3%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: MRC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MRC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
19891,470Wieslaw Zyznowskihttps://mercatormedical.eu

Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally. The company offers surgical and protective, sterile examination and protective, and household gloves; glove brackets; and single-use clothing, including caps, masks, gowns, shoe covers, surgical shirts, sleeve protectors, and patient’s shirts. It also provides surgical drape sheets; sterile drapes with non-adhesive opening; surgical sets; and accessories, such as apparatus covers, limb protectors, table covers, camera covers, adhesive pockets for surgical instruments, and self-adhesive nonwoven tapes.

Mercator Medical Fundamentals Summary

How do Mercator Medical's earnings and revenue compare to its market cap?
MRC fundamental statistics
Market Capzł516.39m
Earnings (TTM)zł167.42m
Revenue (TTM)zł1.31b

3.1x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRC income statement (TTM)
Revenuezł1.31b
Cost of Revenuezł879.18m
Gross Profitzł433.57m
Other Expenseszł266.15m
Earningszł167.42m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Sep 30, 2022

Earnings per share (EPS)15.72
Gross Margin33.03%
Net Profit Margin12.75%
Debt/Equity Ratio0%

How did MRC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MRC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRC?

Other financial metrics that can be useful for relative valuation.

MRC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Earnings Ratio vs Peers

How does MRC's PE Ratio compare to its peers?

MRC PE Ratio vs Peers
The above table shows the PE ratio for MRC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average54.3x
BMX BioMaxima
3.7xn/azł104.7m
VOX Voxel
7.2xn/azł358.1m
EMC EMC Instytut Medyczny
186xn/azł489.1m
SNT Synektik Spólka Akcyjna
20.3xn/azł227.3m
MRC Mercator Medical
3.1xn/azł516.4m

Price-To-Earnings vs Peers: MRC is good value based on its Price-To-Earnings Ratio (3.1x) compared to the peer average (54.3x).


Price to Earnings Ratio vs Industry

How does MRC's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Earnings vs Industry: MRC is good value based on its Price-To-Earnings Ratio (3.1x) compared to the European Medical Equipment industry average (24.7x)


Price to Earnings Ratio vs Fair Ratio

What is MRC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MRC's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MRC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MRC (PLN48.5) is trading below our estimate of fair value (PLN83.07)

Significantly Below Fair Value: MRC is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Mercator Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.8%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mercator Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Mercator Medical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Mercator Medical competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Mercator Medical performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


67.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MRC has high quality earnings.

Growing Profit Margin: MRC's current net profit margins (12.8%) are lower than last year (54.7%).


Past Earnings Growth Analysis

Earnings Trend: MRC's earnings have grown significantly by 67.3% per year over the past 5 years.

Accelerating Growth: MRC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MRC had negative earnings growth (-86%) over the past year, making it difficult to compare to the Medical Equipment industry average (2%).


Return on Equity

High ROE: MRC's Return on Equity (14.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Mercator Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MRC's short term assets (PLN912.9M) exceed its short term liabilities (PLN132.0M).

Long Term Liabilities: MRC's short term assets (PLN912.9M) exceed its long term liabilities (PLN10.6M).


Debt to Equity History and Analysis

Debt Level: MRC is debt free.

Reducing Debt: MRC has no debt compared to 5 years ago when its debt to equity ratio was 43.7%.

Debt Coverage: MRC has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MRC has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Mercator Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: MRC is not paying a notable dividend for the Polish market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MRC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Wieslaw Zyznowski (58 yo)

12.67yrs

Tenure

zł4,449,000

Compensation

Dr. Wies aw yznowski, Phd., serves as the Chairman of Management Board at Mercator Medical Splka Akcyjna since 2010. In the 90s Dr. yznowski co-founded the Mercator. From 1991 to 2001 he served as (apar...


CEO Compensation Analysis

Compensation vs Market: Wieslaw's total compensation ($USD911.53K) is above average for companies of similar size in the Polish market ($USD253.24K).

Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: MRC's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: MRC's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 21 shareholders own 56.91% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
51.51%
Anabaza RAIF V.C.I.C. Ltd
5,484,036PLN266.0m0%no data
3.66%
Wieslaw Zyznowski
389,739PLN18.9m0%no data
1.33%
NN Investment Partners Holdings N.V.
141,954PLN6.9m833.11%no data
0.13%
Dimensional Fund Advisors LP
13,681PLN663.5k-0.25%no data
0.081%
Urszula Zyznowska
8,655PLN419.8k0%no data
0.046%
State Street Global Advisors, Inc.
4,937PLN239.4k3.87%no data
0.026%
BNPP Asset Management Holding
2,812PLN136.4k0%no data
0.022%
Franklin Resources, Inc.
2,352PLN114.1k9.55%no data
0.019%
Piotr Solorz
2,006PLN97.3k0%no data
0.018%
PKO Towarzystwo Funduszy Inwestycyjnych SA
1,863PLN90.4k2.42%no data
0.014%
Towarzystwo Funduszy Inwestycyjnych BGZ BNP Paribas S.A.
1,460PLN70.8k0%0.05%
0.012%
Towarzystwo Funduszy Inwestycyjnych PZU SA
1,285PLN62.3k-96.2%no data
0.01%
AXA Investment Managers S.A.
1,100PLN53.4k0%no data
0.0094%
Witold Kruszewski
1,000PLN48.5k0%no data
0.0068%
Artico Partners AG
727PLN35.3k0%0.01%
0.0066%
Ipopema Towarzystwo Funduszy Inwestycyjnych S.A.
700PLN34.0k0%0.01%
0.005%
Santander Asset Management, S.A., S.G.I.I.C.
536PLN26.0k0%no data
0.0026%
American Century Investment Management Inc
276PLN13.4k-33.81%no data
0.0023%
PGIM, Inc.
246PLN11.9k0%no data
0.0023%
The Vanguard Group, Inc.
246PLN11.9k0%no data
0.0016%
Rockbridge TFI S.A.
173PLN8.4k0%no data

Company Information

Mercator Medical S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Mercator Medical S.A.
  • Ticker: MRC
  • Exchange: WSE
  • Founded: 1989
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: zł516.388m
  • Shares outstanding: 10.65m
  • Website: https://mercatormedical.eu

Number of Employees


Location

  • Mercator Medical S.A.
  • ul. Heleny Modrzejewskiej 30
  • Kraków
  • 31-327
  • Poland


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRCWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNJan 2014
0QJMLSE (London Stock Exchange)YesBearer SharesGBPLNJan 2014
MM2BST (Boerse-Stuttgart)YesBearer SharesDEEURJan 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.